PH12022552813A1 - Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof - Google Patents
Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereofInfo
- Publication number
- PH12022552813A1 PH12022552813A1 PH1/2022/552813A PH12022552813A PH12022552813A1 PH 12022552813 A1 PH12022552813 A1 PH 12022552813A1 PH 12022552813 A PH12022552813 A PH 12022552813A PH 12022552813 A1 PH12022552813 A1 PH 12022552813A1
- Authority
- PH
- Philippines
- Prior art keywords
- kinase inhibitors
- structurally similar
- inhibitors
- dasatinib
- abl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20170641.3A EP3901151B1 (en) | 2020-04-21 | 2020-04-21 | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
| PCT/EP2021/060338 WO2021214117A1 (en) | 2020-04-21 | 2021-04-21 | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022552813A1 true PH12022552813A1 (en) | 2024-03-25 |
Family
ID=71108343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/552813A PH12022552813A1 (en) | 2020-04-21 | 2021-04-21 | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230348453A1 (https=) |
| EP (2) | EP3901151B1 (https=) |
| JP (1) | JP2023522124A (https=) |
| KR (1) | KR20230015343A (https=) |
| CN (1) | CN115667255B (https=) |
| AU (1) | AU2021258431A1 (https=) |
| BR (1) | BR112022021476A2 (https=) |
| CA (1) | CA3176325A1 (https=) |
| CL (1) | CL2022002899A1 (https=) |
| CO (1) | CO2022016245A2 (https=) |
| CR (1) | CR20220528A (https=) |
| IL (1) | IL297481A (https=) |
| MX (1) | MX2022013160A (https=) |
| PE (1) | PE20230462A1 (https=) |
| PH (1) | PH12022552813A1 (https=) |
| TW (1) | TW202204352A (https=) |
| WO (1) | WO2021214117A1 (https=) |
| ZA (1) | ZA202212631B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| AU2021230289A1 (en) | 2020-03-03 | 2022-09-29 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| JP2024534127A (ja) | 2021-08-25 | 2024-09-18 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| KR20240115232A (ko) * | 2021-10-19 | 2024-07-25 | 아이오엠엑스 테라퓨틱스 아게 | Sik3 억제제 및 이의 중간체를 제조하기 위한 합성 반응식 및 과정 |
| US20230212522A1 (en) * | 2022-01-05 | 2023-07-06 | The Board Of Regents Of The University Of Texas System | Methods and reagents for characterizing thsd1 function |
| EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
| EP4257132A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Sik3 inhibitors for treating diseases resistant to death receptor signalling |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2025157389A1 (en) | 2024-01-22 | 2025-07-31 | Iomx Therapeutics Ag | Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors |
| WO2025229127A1 (en) | 2024-04-30 | 2025-11-06 | Iomx Therapeutics Ag | A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors |
| EP4643861A1 (en) | 2024-04-30 | 2025-11-05 | iOmx Therapeutics AG | A halogenated-heteroaryl kinase inhbitor for treating soft tissue sarcoma and vascular tumors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4475916A (en) | 1982-03-18 | 1984-10-09 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| ATE394102T1 (de) * | 2000-06-28 | 2008-05-15 | Astrazeneca Ab | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren |
| RU2368602C2 (ru) | 2005-01-26 | 2009-09-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназ |
| AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| US20100113520A1 (en) * | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CN103172627B (zh) * | 2011-12-26 | 2015-11-18 | 南京优科生物医药有限公司 | 杂环嘧啶苯或吡啶苯类化合物及其应用 |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| AU2015300782B2 (en) | 2014-08-08 | 2020-04-16 | Dana-Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (SIK) inhibitors |
| CN106699744B (zh) * | 2015-11-18 | 2021-05-11 | 四川海思科制药有限公司 | 一种杂环类酰胺衍生物及其制备方法和在药学上的应用 |
| BR112019017741A2 (pt) | 2017-02-28 | 2020-04-07 | Dana Farber Cancer Inst Inc | usos de pirimidopirimidinonas como inibidores de sik |
| DK3391907T3 (da) | 2017-04-20 | 2020-03-09 | Iomx Therapeutics Ag | Intracellulær kinase sik3, der er associeret med resistens over for antitumorimmunresponser, og anvendelser deraf |
| DK3643713T3 (da) * | 2018-10-23 | 2025-11-03 | Iomx Therapeutics Ag | Heterocykliske kinaseinhibitorer og deres anvendelse |
-
2020
- 2020-04-21 EP EP20170641.3A patent/EP3901151B1/en active Active
-
2021
- 2021-04-21 TW TW110114388A patent/TW202204352A/zh unknown
- 2021-04-21 PH PH1/2022/552813A patent/PH12022552813A1/en unknown
- 2021-04-21 CN CN202180027921.5A patent/CN115667255B/zh active Active
- 2021-04-21 CA CA3176325A patent/CA3176325A1/en active Pending
- 2021-04-21 MX MX2022013160A patent/MX2022013160A/es unknown
- 2021-04-21 PE PE2022002448A patent/PE20230462A1/es unknown
- 2021-04-21 IL IL297481A patent/IL297481A/en unknown
- 2021-04-21 JP JP2022563872A patent/JP2023522124A/ja active Pending
- 2021-04-21 KR KR1020227040346A patent/KR20230015343A/ko active Pending
- 2021-04-21 EP EP21718920.8A patent/EP4139305A1/en active Pending
- 2021-04-21 CR CR20220528A patent/CR20220528A/es unknown
- 2021-04-21 US US17/996,514 patent/US20230348453A1/en active Pending
- 2021-04-21 BR BR112022021476A patent/BR112022021476A2/pt unknown
- 2021-04-21 WO PCT/EP2021/060338 patent/WO2021214117A1/en not_active Ceased
- 2021-04-21 AU AU2021258431A patent/AU2021258431A1/en active Pending
-
2022
- 2022-10-20 CL CL2022002899A patent/CL2022002899A1/es unknown
- 2022-11-11 CO CONC2022/0016245A patent/CO2022016245A2/es unknown
- 2022-11-21 ZA ZA2022/12631A patent/ZA202212631B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021258431A1 (en) | 2022-11-17 |
| PE20230462A1 (es) | 2023-03-14 |
| CN115667255A (zh) | 2023-01-31 |
| EP4139305A1 (en) | 2023-03-01 |
| US20230348453A1 (en) | 2023-11-02 |
| WO2021214117A1 (en) | 2021-10-28 |
| CL2022002899A1 (es) | 2023-06-30 |
| CA3176325A1 (en) | 2021-10-28 |
| ZA202212631B (en) | 2023-07-26 |
| MX2022013160A (es) | 2023-02-09 |
| JP2023522124A (ja) | 2023-05-26 |
| EP3901151A1 (en) | 2021-10-27 |
| CR20220528A (es) | 2023-07-13 |
| EP3901151B1 (en) | 2026-04-01 |
| BR112022021476A2 (pt) | 2023-04-04 |
| IL297481A (en) | 2022-12-01 |
| CN115667255B (zh) | 2025-10-28 |
| KR20230015343A (ko) | 2023-01-31 |
| CO2022016245A2 (es) | 2023-02-27 |
| TW202204352A (zh) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552813A1 (en) | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof | |
| WO2021219731A3 (en) | Bicyclic kinase inhibitors and uses thereof | |
| CR20220537A (es) | [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2 | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| CR20220614A (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer | |
| Shen et al. | Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum | |
| MX2024000357A (es) | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). | |
| ZA202403924B (en) | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators | |
| MX2024004444A (es) | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). | |
| MX2021004568A (es) | Inhibidores de cinasa heterociclicos y usos de los mismos. | |
| NZ795548A (en) | Allosteric egfr inhibitors and methods of use thereof | |
| EP4552631A3 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| EP4420728A3 (en) | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof | |
| TN2014000255A1 (en) | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors | |
| IL260127B (en) | mek inhibitors and methods of using them | |
| WO2019197605A3 (en) | Drug combinations for use in the treatment of ras-mutant cancer | |
| BR112017007239A2 (pt) | inibidor da aurora a cinase, seus usos, e composição farmacêutica". | |
| TNSN08375A1 (en) | Quinazolines for pdk1 inhibition | |
| WO2005097137A3 (en) | Advanced quinazoline based protein kinase inhibitors | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| WO2019202160A3 (en) | A 5-thiazolecarboxamide kinase inhibitor and uses thereof | |
| MX2023000577A (es) | Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa. | |
| AU2018284249A1 (en) | Aminothiazole compounds as protein kinase inhibitors | |
| IL307402A (en) | The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer | |
| Antczak et al. | Structure–activity relationships of 6-(2, 6-dichlorophenyl)-8-methyl-2-(phenylamino) pyrido [2, 3-d] pyrimidin-7-ones: toward selective Abl inhibitors |